Showing results (881-890 of 901) with videos related to

Sort By:
Pageof 91
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 7, 2024
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancerRachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen, et al.
Journal of Clinical Medicine|January 11, 2022
Association of Circulating Osteoprotegerin Level with Blood Pressure Variability in Patients with Chronic Kidney DiseaseSang Heon Suh, Tae Ryom Oh, Hong Sang Choi, et al.
Cell Reports|November 23, 2022
The oncogenic JAG1 intracellular domain is a transcriptional cofactor that acts in concert with DDX17/SMAD3/TGIF2Eun-Jung Kim, Jung Yun Kim, Sung-Ok Kim, et al.
The Journal of Obstetrics and Gynaecology Research|December 10, 2019
Effectiveness of adjuvant treatment for morcellated, International Federation of Gynecology and Obstetrics stage I uterine leiomyosarcoma: A Korean multicenter studySe Ik Kim, Chel Hun Choi, Kidong Kim, et al.
Mayo Clinic Proceedings|December 30, 2019
Alcohol Consumption and Progression of Chronic Kidney Disease: Results From the Korean Cohort Study for Outcome in Patients with Chronic Kidney DiseaseYoung Su Joo, Heebyung Koh, Ki Heon Nam, et al.
Nutrients|October 23, 2021
Association of Body Weight Variability with Adverse Cardiovascular Outcomes in Patients with Pre-Dialysis Chronic Kidney DiseaseSang Heon Suh, Tae Ryom Oh, Hong Sang Choi, et al.
Plos One|July 9, 2014
Optimal proteinuria target for renoprotection in patients with IgA nephropathyKi Heon Nam, Jeong Hae Kie, Mi Jung Lee, et al.
The Lancet. Oncology|January 18, 2026
Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trialNatalie Y L Ngoi, Jung-Yun Lee, Diana Lim, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 6, 2026
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trialChristian Marth, Richard G Moore, Mariusz Bidziński, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2024
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III TrialChristian Marth, Richard G Moore, Mariusz Bidziński, et al.
Pageof 91